Implementing consultation audio recording applications to improve informed decision-making (IDM) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) eligible for docetaxel. Read more about Implementing consultation audio recording applications to improve informed decision-making (IDM) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) eligible for docetaxel.
Somatostatin receptor 1 ( SSTR1 ) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC). Read more about Somatostatin receptor 1 ( SSTR1 ) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC).
Association of a prostate cancer gastrointestinal transcriptional phenotype as found in clinical mCRPC samples with response to AR-targeted therapy. Read more about Association of a prostate cancer gastrointestinal transcriptional phenotype as found in clinical mCRPC samples with response to AR-targeted therapy.
Advancing the drug development process in metastatic prostate cancer through machine learning. Read more about Advancing the drug development process in metastatic prostate cancer through machine learning.
A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC) Read more about A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC)
Prognostic evaluation of surgical re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group. Read more about Prognostic evaluation of surgical re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors. Read more about Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.
Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC). Read more about Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: A single center retrospective cohort study. Read more about Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: A single center retrospective cohort study.
The voice of the breast cancer survivor: Implementation of survivorship needs assessment in an integrated health system. Read more about The voice of the breast cancer survivor: Implementation of survivorship needs assessment in an integrated health system.
